| Name | Title | Contact Details |
|---|
American Nuclear Insurers (ANI) is a joint underwriting association created by some of the largest insurance companies in the United States. Our purpose is to pool the financial assets pledged by our member companies to provide the significant amount of property and liability insurance required for nuclear power plants and related facilities throughout the world.
With a global footprint spanning Europe, North and South America, Asia, and Africa, Sodecia operates business units that partner with the worlds leading automakers to develop innovative products and services. We specialize in stamping and welding, producing high-quality automotive components. Our technology centers in Europe provide comprehensive collaborative engineering services, delivering solutions that add value through advanced technologies, sustainability, agility, simplicity, and customer satisfaction. Sustainability is at the heart of our operations. We are committed to reducing our environmental impact through various initiatives, including the implementation of cutting-edge technologies and sustainable practices. Our dedication to sustainability ensures that we are not only meeting the needs of today but also preserving resources for future generations. At Sodecia, we believe in continuous improvement and innovation. Our global team is dedicated to enhancing the quality of life through the development of solutions for the automotive sector. Together, we are driving forward to create a safer, more efficient, and sustainable future. Explore more about our mission and values on our website.
Mold Law Groups litigation platform is a culmination of over 15 years of in-depth research by environmentalists, epidemiologists, toxicologists, medical professionals, Neurotoxicologists, Neuropsychologists, and law firms. Our proven methodology, for the first time, provides litigators the ability to couple the human pathogens in an environment to the direct causation of disease within the human body. The development of this cutting-edge science required an understanding of many different scientific disciplines and medical philosophies to provide a unique and new model for mold litigation. This platform is designed to defend or prosecute property and medical damages caused by mold and microbial exposure. Using precision based DNA-PCR sequencing, bacteria culturing, endotoxin testing, (1—>3)β-D beta glucan and other advanced environmental and medical testing, we leverage cutting edge technology and advanced mold litigation techniques to provide our clients with unparalleled and detailed services found nowhere else in our industry. Mold Law Group offers expert witnesses, consulting services, medical resources, legal resources, and environmental resources. We offer these services nationally and internationally. Mold Law Group is the absolute gold standard when it comes to mold litigation consulting.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.